This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2004 Jan 1;22(1):7-10.

doi: 10.1200/JCO.2004.10.907. Epub 2003 Dec 9.

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

Lynn M Schuchter

PMID: 14665612
DOI: 10.1200/JCO.2004.10.907

Editorial

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

Lynn M Schuchter. J Clin Oncol. 2004.

. 2004 Jan 1;22(1):7-10.

doi: 10.1200/JCO.2004.10.907. Epub 2003 Dec 9.

Author

Lynn M Schuchter

PMID: 14665612
DOI: 10.1200/JCO.2004.10.907

No abstract available

PubMed Disclaimer

Comment in

Adjuvant interferon therapy for melanoma.
Hancock B, Wheatley K, Ives N, Gore M. Hancock B, et al. J Clin Oncol. 2005 Apr 1;23(10):2431; author reply 2431-2. doi: 10.1200/JCO.2005.99.260. J Clin Oncol. 2005. PMID: 15800339 No abstract available.

Comment on

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Hancock BW, et al. J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665609 Clinical Trial.

Similar articles

Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Moschos SJ, et al. J Clin Oncol. 2004 Jan 1;22(1):11-4. doi: 10.1200/JCO.2004.10.952. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665613 No abstract available.
Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Hancock BW, et al. J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9. J Clin Oncol. 2004. PMID: 14665609 Clinical Trial.
Adjuvant therapy for malignant melanoma.
Stoutenburg JP, Schrope B, Kaufman HL. Stoutenburg JP, et al. Expert Rev Anticancer Ther. 2004 Oct;4(5):823-35. doi: 10.1586/14737140.4.5.823. Expert Rev Anticancer Ther. 2004. PMID: 15485316 Review.
Adjuvant interferon therapy for melanoma.
Hancock B, Wheatley K, Ives N, Gore M. Hancock B, et al. J Clin Oncol. 2005 Apr 1;23(10):2431; author reply 2431-2. doi: 10.1200/JCO.2005.99.260. J Clin Oncol. 2005. PMID: 15800339 No abstract available.
Current management of melanoma: benefits of surgical staging and adjuvant therapy.
McMasters KM, Swetter SM. McMasters KM, et al. J Surg Oncol. 2003 Mar;82(3):209-16. doi: 10.1002/jso.10216. J Surg Oncol. 2003. PMID: 12619066 Review.

See all similar articles

Cited by

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.
Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS. Mohr P, et al. Melanoma Manag. 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015. Melanoma Manag. 2019. PMID: 31871622 Free PMC article.
Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities.
Boussios S, Sheriff M, Rassy E, Moschetta M, Samartzis EP, Hallit R, Sadauskaite A, Katsanos KH, Christodoulou DK, Pavlidis N. Boussios S, et al. Ann Transl Med. 2021 Mar;9(5):423. doi: 10.21037/atm-20-7361. Ann Transl Med. 2021. PMID: 33842644 Free PMC article. Review.
Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.
Rubanov A, Berico P, Hernando E. Rubanov A, et al. Cancers (Basel). 2022 Nov 28;14(23):5858. doi: 10.3390/cancers14235858. Cancers (Basel). 2022. PMID: 36497341 Free PMC article. Review.
Recent advances in sunlight-induced carcinogenesis using the Xiphophorus melanoma model.
Fernandez AA, Paniker L, Garcia R, Mitchell DL. Fernandez AA, et al. Comp Biochem Physiol C Toxicol Pharmacol. 2012 Jan;155(1):64-70. doi: 10.1016/j.cbpc.2011.03.007. Epub 2011 Mar 30. Comp Biochem Physiol C Toxicol Pharmacol. 2012. PMID: 21457786 Free PMC article.
Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.
Ventola CL. Ventola CL. P T. 2017 Jul;42(7):452-463. P T. 2017. PMID: 28674473 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information